サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：放射線皮膚炎の世界市場 (2022～2030年)：成長・将来の展望・競合分析
市場調査レポート
商品コード
1182403

放射線皮膚炎の世界市場 (2022～2030年)：成長・将来の展望・競合分析

Radiodermatitis Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030
出版日: | 発行: Acute Market Reports | ページ情報: 英文 116 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
放射線皮膚炎の世界市場 (2022～2030年)：成長・将来の展望・競合分析
出版日: 2022年08月12日
発行: Acute Market Reports
ページ情報: 英文 116 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

放射線皮膚炎の市場は、放射線療法を選択する患者の癌の有病率の上昇、痛みを最小限に抑えて治癒を促進するハイドロコロイドやハイドロゲルなどの薬剤の技術的進歩などの要因によって推進されています。さらに、病因に関する医師の意識の高まりや、安価で販売・購入できるオンラインマーケティングの増加が治療の市場への浸透を促進しています。

2021年には、局所剤の部門が最大のシェアを占めました。これは主に、副腎皮質ホルモンが放射線皮膚炎の治療のゴールドスタンダードと考えられていることや、親水性クリームが乾燥した落屑皮膚領域に水分を供給して患者の不快感を最小限に抑えるなどの要因によるものです。

当レポートでは、世界の放射線皮膚炎の市場を調査し、市場概要、市場成長への各種影響因子の分析、市場規模の推移・予測、各種区分・地域/主要国別の内訳、主要企業のプロファイルなどをまとめています。

目次

第1章 序文

第2章 エグゼクティブサマリー

第3章 放射線皮膚炎市場：競合分析

  • ベンダーの市場における位置づけ
  • ベンダーの採用戦略
  • 主要産業戦略
  • ティア分析：2021年・2030年

第4章 放射線皮膚炎市場：マクロ分析・市場力学

  • 世界市場の規模：2020-2030年
  • 市場力学
    • 市場促進要因
    • 市場抑制要因
    • 主な課題
    • 主な機会
  • 促進要因・抑制要因の影響分析
  • シーソー分析

第5章 放射線皮膚炎市場：製品別

  • 市場概要
  • 成長・収益分析：2021年・2030年
  • 市場の分類
    • 局所剤
    • ドレッシング材
    • 経口剤

第6章 北米の放射線皮膚炎市場

  • 市場概要
  • 放射線皮膚炎市場：製品別
  • 放射線皮膚炎市場：地域別

第7章 英国およびEUの放射線皮膚炎市場

  • 市場概要
  • 放射線皮膚炎市場：製品別
  • 放射線皮膚炎市場：地域別

第8章 アジア太平洋の放射線皮膚炎市場

  • 市場概要
  • 放射線皮膚炎市場：製品別
  • 放射線皮膚炎市場：地域別

第9章 ラテンアメリカの放射線皮膚炎市場

  • 市場概要
  • 放射線皮膚炎市場：製品別
  • 放射線皮膚炎市場：地域別

第10章 中東およびアフリカの放射線皮膚炎市場

  • 市場概要
  • 放射線皮膚炎市場：製品別
  • 放射線皮膚炎市場：地域別

第11章 企業プロファイル

  • Acelity
  • Alliqua Biomedical
  • BMG Pharma S.R.L.
  • Convatec, Inc.
  • Derma Sciences, Inc.
  • Intermed Pharmaceuticals
  • Molnlycke Health Care AB
  • Smith & Nephew plc
  • Stratpharma AG
  • 3M Healthcare
  • 他の主要企業
図表

List of Tables

  • TABLE 1 Global Radiodermatitis Market By Product, 2020-2030, USD (Million)
  • TABLE 2 Global Radiodermatitis Market By Topical, 2020-2030, USD (Million)
  • TABLE 3 Global Radiodermatitis Market By Dressing, 2020-2030, USD (Million)
  • TABLE 4 North America Radiodermatitis Market By Product, 2020-2030, USD (Million)
  • TABLE 5 North America Radiodermatitis Market By Topical, 2020-2030, USD (Million)
  • TABLE 6 North America Radiodermatitis Market By Dressing, 2020-2030, USD (Million)
  • TABLE 7 U.S. Radiodermatitis Market By Product, 2020-2030, USD (Million)
  • TABLE 8 U.S. Radiodermatitis Market By Topical, 2020-2030, USD (Million)
  • TABLE 9 U.S. Radiodermatitis Market By Dressing, 2020-2030, USD (Million)
  • TABLE 10 Canada Radiodermatitis Market By Product, 2020-2030, USD (Million)
  • TABLE 11 Canada Radiodermatitis Market By Topical, 2020-2030, USD (Million)
  • TABLE 12 Canada Radiodermatitis Market By Dressing, 2020-2030, USD (Million)
  • TABLE 13 Rest of North America Radiodermatitis Market By Product, 2020-2030, USD (Million)
  • TABLE 14 Rest of North America Radiodermatitis Market By Topical, 2020-2030, USD (Million)
  • TABLE 15 Rest of North America Radiodermatitis Market By Dressing, 2020-2030, USD (Million)
  • TABLE 16 UK and European Union Radiodermatitis Market By Product, 2020-2030, USD (Million)
  • TABLE 17 UK and European Union Radiodermatitis Market By Topical, 2020-2030, USD (Million)
  • TABLE 18 UK and European Union Radiodermatitis Market By Dressing, 2020-2030, USD (Million)
  • TABLE 19 UK Radiodermatitis Market By Product, 2020-2030, USD (Million)
  • TABLE 20 UK Radiodermatitis Market By Topical, 2020-2030, USD (Million)
  • TABLE 21 UK Radiodermatitis Market By Dressing, 2020-2030, USD (Million)
  • TABLE 22 Germany Radiodermatitis Market By Product, 2020-2030, USD (Million)
  • TABLE 23 Germany Radiodermatitis Market By Topical, 2020-2030, USD (Million)
  • TABLE 24 Germany Radiodermatitis Market By Dressing, 2020-2030, USD (Million)
  • TABLE 25 Spain Radiodermatitis Market By Product, 2020-2030, USD (Million)
  • TABLE 26 Spain Radiodermatitis Market By Topical, 2020-2030, USD (Million)
  • TABLE 27 Spain Radiodermatitis Market By Dressing, 2020-2030, USD (Million)
  • TABLE 28 Italy Radiodermatitis Market By Product, 2020-2030, USD (Million)
  • TABLE 29 Italy Radiodermatitis Market By Topical, 2020-2030, USD (Million)
  • TABLE 30 Italy Radiodermatitis Market By Dressing, 2020-2030, USD (Million)
  • TABLE 31 France Radiodermatitis Market By Product, 2020-2030, USD (Million)
  • TABLE 32 France Radiodermatitis Market By Topical, 2020-2030, USD (Million)
  • TABLE 33 France Radiodermatitis Market By Dressing, 2020-2030, USD (Million)
  • TABLE 34 Rest of Europe Radiodermatitis Market By Product, 2020-2030, USD (Million)
  • TABLE 35 Rest of Europe Radiodermatitis Market By Topical, 2020-2030, USD (Million)
  • TABLE 36 Rest of Europe Radiodermatitis Market By Dressing, 2020-2030, USD (Million)
  • TABLE 37 Asia Radiodermatitis Market By Product, 2020-2030, USD (Million)
  • TABLE 38 Asia Radiodermatitis Market By Topical, 2020-2030, USD (Million)
  • TABLE 39 Asia Radiodermatitis Market By Dressing, 2020-2030, USD (Million)
  • TABLE 40 China Radiodermatitis Market By Product, 2020-2030, USD (Million)
  • TABLE 41 China Radiodermatitis Market By Topical, 2020-2030, USD (Million)
  • TABLE 42 China Radiodermatitis Market By Dressing, 2020-2030, USD (Million)
  • TABLE 43 Japan Radiodermatitis Market By Product, 2020-2030, USD (Million)
  • TABLE 44 Japan Radiodermatitis Market By Topical, 2020-2030, USD (Million)
  • TABLE 45 Japan Radiodermatitis Market By Dressing, 2020-2030, USD (Million)
  • TABLE 46 India Radiodermatitis Market By Product, 2020-2030, USD (Million)
  • TABLE 47 India Radiodermatitis Market By Topical, 2020-2030, USD (Million)
  • TABLE 48 India Radiodermatitis Market By Dressing, 2020-2030, USD (Million)
  • TABLE 49 Australia Radiodermatitis Market By Product, 2020-2030, USD (Million)
  • TABLE 50 Australia Radiodermatitis Market By Topical, 2020-2030, USD (Million)
  • TABLE 51 Australia Radiodermatitis Market By Dressing, 2020-2030, USD (Million)
  • TABLE 52 South Korea Radiodermatitis Market By Product, 2020-2030, USD (Million)
  • TABLE 53 South Korea Radiodermatitis Market By Topical, 2020-2030, USD (Million)
  • TABLE 54 South Korea Radiodermatitis Market By Dressing, 2020-2030, USD (Million)
  • TABLE 55 Latin America Radiodermatitis Market By Product, 2020-2030, USD (Million)
  • TABLE 56 Latin America Radiodermatitis Market By Topical, 2020-2030, USD (Million)
  • TABLE 57 Latin America Radiodermatitis Market By Dressing, 2020-2030, USD (Million)
  • TABLE 58 Brazil Radiodermatitis Market By Product, 2020-2030, USD (Million)
  • TABLE 59 Brazil Radiodermatitis Market By Topical, 2020-2030, USD (Million)
  • TABLE 60 Brazil Radiodermatitis Market By Dressing, 2020-2030, USD (Million)
  • TABLE 61 Mexico Radiodermatitis Market By Product, 2020-2030, USD (Million)
  • TABLE 62 Mexico Radiodermatitis Market By Topical, 2020-2030, USD (Million)
  • TABLE 63 Mexico Radiodermatitis Market By Dressing, 2020-2030, USD (Million)
  • TABLE 64 Rest of Latin America Radiodermatitis Market By Product, 2020-2030, USD (Million)
  • TABLE 65 Rest of Latin America Radiodermatitis Market By Topical, 2020-2030, USD (Million)
  • TABLE 66 Rest of Latin America Radiodermatitis Market By Dressing, 2020-2030, USD (Million)
  • TABLE 67 Middle East and Africa Radiodermatitis Market By Product, 2020-2030, USD (Million)
  • TABLE 68 Middle East and Africa Radiodermatitis Market By Topical, 2020-2030, USD (Million)
  • TABLE 69 Middle East and Africa Radiodermatitis Market By Dressing, 2020-2030, USD (Million)
  • TABLE 70 GCC Radiodermatitis Market By Product, 2020-2030, USD (Million)
  • TABLE 71 GCC Radiodermatitis Market By Topical, 2020-2030, USD (Million)
  • TABLE 72 GCC Radiodermatitis Market By Dressing, 2020-2030, USD (Million)
  • TABLE 73 Africa Radiodermatitis Market By Product, 2020-2030, USD (Million)
  • TABLE 74 Africa Radiodermatitis Market By Topical, 2020-2030, USD (Million)
  • TABLE 75 Africa Radiodermatitis Market By Dressing, 2020-2030, USD (Million)
  • TABLE 76 Rest of Middle East and Africa Radiodermatitis Market By Product, 2020-2030, USD (Million)
  • TABLE 77 Rest of Middle East and Africa Radiodermatitis Market By Topical, 2020-2030, USD (Million)
  • TABLE 78 Rest of Middle East and Africa Radiodermatitis Market By Dressing, 2020-2030, USD (Million)

List of Figures

  • FIG. 1 Global Radiodermatitis Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Radiodermatitis Market: Quality Assurance
  • FIG. 5 Global Radiodermatitis Market, By Product, 2021
  • FIG. 6 Global Radiodermatitis Market, By Geography, 2021
  • FIG. 7 Market Geographical Opportunity Matrix - Global Radiodermatitis Market, 2021
  • FIG. 8 Market Positioning of Key Radiodermatitis Market Players, 2021
  • FIG. 9 Global Radiodermatitis Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
  • FIG. 10 Global Radiodermatitis Market, By Product, 2021 Vs 2030, %
  • FIG. 11 U.S. Radiodermatitis Market (US$ Million), 2020 - 2030
  • FIG. 12 Canada Radiodermatitis Market (US$ Million), 2020 - 2030
  • FIG. 13 Rest of North America Radiodermatitis Market (US$ Million), 2020 - 2030
  • FIG. 14 UK Radiodermatitis Market (US$ Million), 2020 - 2030
  • FIG. 15 Germany Radiodermatitis Market (US$ Million), 2020 - 2030
  • FIG. 16 Spain Radiodermatitis Market (US$ Million), 2020 - 2030
  • FIG. 17 Italy Radiodermatitis Market (US$ Million), 2020 - 2030
  • FIG. 18 France Radiodermatitis Market (US$ Million), 2020 - 2030
  • FIG. 19 Rest of Europe Radiodermatitis Market (US$ Million), 2020 - 2030
  • FIG. 20 China Radiodermatitis Market (US$ Million), 2020 - 2030
  • FIG. 21 Japan Radiodermatitis Market (US$ Million), 2020 - 2030
  • FIG. 22 India Radiodermatitis Market (US$ Million), 2020 - 2030
  • FIG. 23 Australia Radiodermatitis Market (US$ Million), 2020 - 2030
  • FIG. 24 South Korea Radiodermatitis Market (US$ Million), 2020 - 2030
  • FIG. 25 Rest of Asia Radiodermatitis Market (US$ Million), 2020 - 2030
  • FIG. 26 Brazil Radiodermatitis Market (US$ Million), 2020 - 2030
  • FIG. 27 Mexico Radiodermatitis Market (US$ Million), 2020 - 2030
  • FIG. 28 Rest of Latin America Radiodermatitis Market (US$ Million), 2020 - 2030
  • FIG. 29 GCC Radiodermatitis Market (US$ Million), 2020 - 2030
  • FIG. 30 Africa Radiodermatitis Market (US$ Million), 2020 - 2030
  • FIG. 31 Rest of Middle East and Africa Radiodermatitis Market (US$ Million), 2020 - 2030
目次
Product Code: 137694-08-22

According to American Society for Radiation Oncology 2010 report approximately 75% of oncology patients opt for radiation therapy. The primary aim of radiation therapy is to irradiate the tumor cells, however the normal cells being exposed to the radiation therapy get damaged. Normal tissue cells are capable of self-repair but the repetitive damage reduces the reparation properties of normal cells. Factors that increase the risk and severity of skin reactions include high daily cumulative radiation doses, the type of beam utilized for irradiation, large treatment field, treatment to areas with skin folds and whether the radiation was given with chemotherapy.

For the purpose of this study, the various products studied includes topical, dressing and oral. Topical are further classified as (antibiotics, hydrophilic creams, corticosteroids and others). Dressing are categorized as (no string barrier films, honey impregnated gauze, hydrogel and hydrocolloid dressings, silicone coated dressings and others).

The geographic segmentation of the global radiodermatitis market is performed for the regions North America, Europe, Asia Pacific, Latin America, and Middle East and Africa markets.

This report also includes qualitative assessment factors such as market dynamics (drivers, restraints, and opportunities) to have a good understanding of the current and anticipated trends in the global radiodermatitis market. Market attractiveness assessment and competitive landscape analysis by key players are also presented in the study. Furthermore, this report concludes with profiling of key market players currently enjoying prominent position in the global radiodermatitis market. The major players in radiodermatitis market are Acelity, Alliqua Biomedical, BMG Pharma S.R.L., Convatec, Inc., Derma Sciences, Inc., Intermed Pharmaceuticals, Molnlycke Health Care AB, Smith & Nephew plc, Stratpharma AG and 3M Healthcare.

The radiodermatitis market is driven by factors such as rising prevalence of cancer with patients opting for radiation therapy, technological advancement in the drug formulation such as hydrocolloids and hydrogels which expedites healing with minimal pain. In addition, rising physician awareness regarding disease etiology and increasing online marketing with affordable sale and purchase options will propel the market penetration of treatments. In 2021, topical segment held the largest market share chiefly due to factors such as corticosteroids are considered as the gold standard for the treatment of radiodermatitis and hydrophilic creams minimizes the patients discomfort by providing moisture to the dry desquamation skin area.

Dressings will be the fastest growing segment throughout the forecast period 2022-2030 majorly due to factors such as rising prevalence of radiodermatitis, wide range of dressings available as per the degree of skin complication due to radiation therapy. The hydrocolloid and hydrogel dressings are finding huge applications as they are used for the management of moist desquamation in order to promote a moist environment for reepithelization. The major players in radiodermatitis market are Acelity, Alliqua Biomedical, BMG Pharma S.R.L., Convatec, Inc., Derma Sciences, Inc., Intermed Pharmaceuticals, Molnlycke Health Care AB, Smith & Nephew plc., Stratpharma AG and 3M Healthcare.

North America will be the fastest-growing market for radiodermatitis throughout the forecast period 2022-2030. According to the American Cancer Society, in 2017, about 1,688,780 new cancer cases were diagnosed. The dominance of North America is mainly attributed to the presence of key drivers such as rising prevalence of cancer, first treatment preference to treat cancer is given to radiation therapy, and developed research and healthcare institutions. The market growth in Europe is mainly attributed to the increasing prevalence of radiodermatitis and rising fashion trend has resulted in the demand for radiation therapy to enhance the aesthetic appeal of personal beauty and affordable reimbursement scenario.

Asia Pacific dominated the radiodermatitis market for the base year 2021 and the factors that are anticipated to propel the market growth are the increasing number of chronic health complications resulting into demand for radiation therapy, competitive market due to presence of existing major and evolving players engaged in the manufacturing and sale of radiodermatitis products in these regions, increasing disposable incomes and supportive regulatory environment for radiodermatitis products. Moreover, factors such as developing healthcare infrastructure, extensive collaborations undertaken by pharmaceutical giants to expand their product portfolio in the untapped markets of developing areas with unmet medical needs are going to fuel the rapid growth of radiodermatitis market in Latin America, and Middle East and Africa region in the near future.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Radiodermatitis market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Radiodermatitis market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Product

  • Topical
    • Antibiotics
    • Hydrophilic Creams
    • Corticosteroids
    • Others
  • Dressing
    • No String Barrier Films
    • Honey Impregnated Gauze
    • Hydrogel and Hydrocolloid Dressings
    • Silicone Coated Dressings
    • Others
  • Oral

Region Segment (2020-2030; US$ Million)

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • UK and European Union
    • UK
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Africa
    • Rest of Middle East and Africa

Global Impact of COVID-19 Segment (2020-2021; US$ Million )

  • Pre COVID-19 situation
  • Post COVID-19 situation

Key questions answered in this report:

  • What are the key micro and macro environmental factors that are impacting the growth of Radiodermatitis market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2030.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Radiodermatitis market?
  • Which is the largest regional market for Radiodermatitis market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Radiodermatitis market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Radiodermatitis market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Radiodermatitis Market
  • 2.2. Global Radiodermatitis Market, By Product, 2021 (US$ Million)
  • 2.3. Global Radiodermatitis Market, By Geography, 2021 (US$ Million)
  • 2.4. Attractive Investment Proposition by Geography, 2021

3. Radiodermatitis Market: Competitive Analysis

  • 3.1. Market Positioning of Key Radiodermatitis Market Vendors
  • 3.2. Strategies Adopted by Radiodermatitis Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2021 Versus 2030

4. Radiodermatitis Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Radiodermatitis Market Value, 2020 - 2030, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis

5. Radiodermatitis Market: By Product, 2020-2030, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 5.3. Market Segmentation
    • 5.3.1. Topical
      • 5.3.1.1. Antibiotics
      • 5.3.1.2. Hydrophilic Creams
      • 5.3.1.3. Corticosteroids
      • 5.3.1.4. Others
    • 5.3.2. Dressing
      • 5.3.2.1. No String Barrier Films
      • 5.3.2.2. Honey Impregnated Gauze
      • 5.3.2.3. Hydrogel and Hydrocolloid Dressings
      • 5.3.2.4. Silicone Coated Dressings
      • 5.3.2.5. Others
    • 5.3.3. Oral

6. North America Radiodermatitis Market, 2020-2030, USD (Million)

  • 6.1. Market Overview
  • 6.2. Radiodermatitis Market: By Product, 2020-2030, USD (Million)
  • 6.3.Radiodermatitis Market: By Region, 2020-2030, USD (Million)
    • 6.3.1.North America
      • 6.3.1.1. U.S.
        • 6.3.1.1.1. Radiodermatitis Market: By Product, 2020-2030, USD (Million)
      • 6.3.1.2. Canada
        • 6.3.1.2.1. Radiodermatitis Market: By Product, 2020-2030, USD (Million)
      • 6.3.1.3. Rest of North America
        • 6.3.1.3.1. Radiodermatitis Market: By Product, 2020-2030, USD (Million)

7. UK and European Union Radiodermatitis Market, 2020-2030, USD (Million)

  • 7.1. Market Overview
  • 7.2. Radiodermatitis Market: By Product, 2020-2030, USD (Million)
  • 7.3.Radiodermatitis Market: By Region, 2020-2030, USD (Million)
    • 7.3.1.UK and European Union
      • 7.3.1.1. UK
        • 7.3.1.1.1. Radiodermatitis Market: By Product, 2020-2030, USD (Million)
      • 7.3.1.2. Germany
        • 7.3.1.2.1. Radiodermatitis Market: By Product, 2020-2030, USD (Million)
      • 7.3.1.3. Spain
        • 7.3.1.3.1. Radiodermatitis Market: By Product, 2020-2030, USD (Million)
      • 7.3.1.4. Italy
        • 7.3.1.4.1. Radiodermatitis Market: By Product, 2020-2030, USD (Million)
      • 7.3.1.5. France
        • 7.3.1.5.1. Radiodermatitis Market: By Product, 2020-2030, USD (Million)
      • 7.3.1.6. Rest of Europe
        • 7.3.1.6.1. Radiodermatitis Market: By Product, 2020-2030, USD (Million)

8. Asia Pacific Radiodermatitis Market, 2020-2030, USD (Million)

  • 8.1. Market Overview
  • 8.2. Radiodermatitis Market: By Product, 2020-2030, USD (Million)
  • 8.3.Radiodermatitis Market: By Region, 2020-2030, USD (Million)
    • 8.3.1.Asia Pacific
      • 8.3.1.1. China
        • 8.3.1.1.1. Radiodermatitis Market: By Product, 2020-2030, USD (Million)
      • 8.3.1.2. Japan
        • 8.3.1.2.1. Radiodermatitis Market: By Product, 2020-2030, USD (Million)
      • 8.3.1.3. India
        • 8.3.1.3.1. Radiodermatitis Market: By Product, 2020-2030, USD (Million)
      • 8.3.1.4. Australia
        • 8.3.1.4.1. Radiodermatitis Market: By Product, 2020-2030, USD (Million)
      • 8.3.1.5. South Korea
        • 8.3.1.5.1. Radiodermatitis Market: By Product, 2020-2030, USD (Million)
      • 8.3.1.6. Rest of Asia Pacific
        • 8.3.1.6.1. Radiodermatitis Market: By Product, 2020-2030, USD (Million)

9. Latin America Radiodermatitis Market, 2020-2030, USD (Million)

  • 9.1. Market Overview
  • 9.2. Radiodermatitis Market: By Product, 2020-2030, USD (Million)
  • 9.3.Radiodermatitis Market: By Region, 2020-2030, USD (Million)
    • 9.3.1.Latin America
      • 9.3.1.1. Brazil
        • 9.3.1.1.1. Radiodermatitis Market: By Product, 2020-2030, USD (Million)
      • 9.3.1.2. Mexico
        • 9.3.1.2.1. Radiodermatitis Market: By Product, 2020-2030, USD (Million)
      • 9.3.1.3. Rest of Latin America
        • 9.3.1.3.1. Radiodermatitis Market: By Product, 2020-2030, USD (Million)

10. Middle East and Africa Radiodermatitis Market, 2020-2030, USD (Million)

  • 10.1. Market Overview
  • 10.2. Radiodermatitis Market: By Product, 2020-2030, USD (Million)
  • 10.3.Radiodermatitis Market: By Region, 2020-2030, USD (Million)
    • 10.3.1.Middle East and Africa
      • 10.3.1.1. GCC
        • 10.3.1.1.1. Radiodermatitis Market: By Product, 2020-2030, USD (Million)
      • 10.3.1.2. Africa
        • 10.3.1.2.1. Radiodermatitis Market: By Product, 2020-2030, USD (Million)
      • 10.3.1.3. Rest of Middle East and Africa
        • 10.3.1.3.1. Radiodermatitis Market: By Product, 2020-2030, USD (Million)

11. Company Profile

  • 11.1. Acelity
    • 11.1.1. Company Overview
    • 11.1.2. Financial Performance
    • 11.1.3. Product Portfolio
    • 11.1.4. Strategic Initiatives
  • 11.2. Alliqua Biomedical
    • 11.2.1. Company Overview
    • 11.2.2. Financial Performance
    • 11.2.3. Product Portfolio
    • 11.2.4. Strategic Initiatives
  • 11.3. BMG Pharma S.R.L.
    • 11.3.1. Company Overview
    • 11.3.2. Financial Performance
    • 11.3.3. Product Portfolio
    • 11.3.4. Strategic Initiatives
  • 11.4. Convatec, Inc.
    • 11.4.1. Company Overview
    • 11.4.2. Financial Performance
    • 11.4.3. Product Portfolio
    • 11.4.4. Strategic Initiatives
  • 11.5. Derma Sciences, Inc.
    • 11.5.1. Company Overview
    • 11.5.2. Financial Performance
    • 11.5.3. Product Portfolio
    • 11.5.4. Strategic Initiatives
  • 11.6. Intermed Pharmaceuticals
    • 11.6.1. Company Overview
    • 11.6.2. Financial Performance
    • 11.6.3. Product Portfolio
    • 11.6.4. Strategic Initiatives
  • 11.7. Molnlycke Health Care AB
    • 11.7.1. Company Overview
    • 11.7.2. Financial Performance
    • 11.7.3. Product Portfolio
    • 11.7.4. Strategic Initiatives
  • 11.8. Smith & Nephew plc
    • 11.8.1. Company Overview
    • 11.8.2. Financial Performance
    • 11.8.3. Product Portfolio
    • 11.8.4. Strategic Initiatives
  • 11.9. Stratpharma AG
    • 11.9.1. Company Overview
    • 11.9.2. Financial Performance
    • 11.9.3. Product Portfolio
    • 11.9.4. Strategic Initiatives
  • 11.10. 3M Healthcare
    • 11.10.1. Company Overview
    • 11.10.2. Financial Performance
    • 11.10.3. Product Portfolio
    • 11.10.4. Strategic Initiatives
  • 11.11. Other Notable Players
    • 11.11.1. Company Overview
    • 11.11.2. Financial Performance
    • 11.11.3. Product Portfolio
    • 11.11.4. Strategic Initiatives